Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder

Journal of Urology

Volumn 181, Issue 6, 2009, Pages 2608-2615

  Flynn, Michael K ^a   Amundsen, Cindy L ^b   Perevich, MaryAnn ^a   Liu, Fan ^a   Webster, George D ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

botulinum toxins; overactive; urge; urinary bladder; urinary incontinence

Indexed keywords

BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; PLACEBO;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BLADDER PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTOSCOPY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; NOCTURIA; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINARY TRACT INFECTION; URINE FLOW RATE; URINE RETENTION; URODYNAMICS;

ADULT; AGED; AGED, 80 AND OVER; BOTULINUM TOXIN TYPE A; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEUROMUSCULAR AGENTS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 67349243753     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.01.117     Document Type: Article

References (20)

1. Weber A., and Walters M. Epidemiology and social impact of urinary and fecal incontinence. Urogynecology and Pelvic Reconstructive Surgery (1999), Mosby, St. Louis, Missouri 25-33
2. Yoshimura N., and Chancellor M.B. Current and future pharmacological treatment for overactive bladder. J Urol 168 (2002) 1897
3. Aoki K.R. Pharmacology and immunology of botulinum toxin serotypes. J Neurol 248 (2001) 3
4. Brin M.F. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve, suppl 6 (1997) S146
5. Jankovic J., and Brin M. Botulinum toxin: historical perspective and potential new indications. Muscle Nerve, suppl 6 (1997) S129
6. Culliere C., Ducrotte P., Zerbib F., Metman E.H., de Looze D., Guillemot F., et al. Achalasia: outcome of patients treated with intrasphincteric injection of botulinum toxin. Gut 41 (1997) 87
7. Schurch B., Hauri D., Rodic B., Curt A., Meyer M., and Rossier A.B. Botulinum-A toxin as a treatment for detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155 (1996) 1023
8. Phelan M.W., Franks M., Somogyi G.T., Yokoyama T., Fraser M.O., Lavelle J.P., et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165 (2001) 1107
9. Schurch B., Stohrer M., Krmaer G., Schmid D.M., Gaul G., and Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs?. Preliminary results. J Urol 164 (2000) 692
10. Schulte-Baukloh H., Michael T., Schobert J., Stolze T., and Knispel H.H. Efficacy of botulinum-a toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59 (2002) 325
11. Schurch B., de Seze M., Denys P., Chartier-Kastler E., Haab F., Everaert K., et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 174 (2005) 196
12. Flynn M.K., Webster G.D., and Amundsen C.L. The effect of botulinum-A toxin on patients with severe urge urinary incontinence. J Urol 172 (2004) 2316
13. Werner M., Schmid D.M., and Schussler B. Efficacy of botulinum-A toxin in the treatment of detrusor overactivity incontinence: a prospective nonrandomized study. Am J Obstet Gynecol 192 (2005) 1735
14. Kuo H.C. Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics. Urology 66 (2005) 94
15. Schmid D.M., Sauermann P., Werner M., Schuessler B., Blick N., Muentener M., et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 176 (2006) 177
16. Schulte-Baukloh H., Weiss C., Stolze T., Herholz J., Sturzebecher B., Miller K., et al. Botulinum-A toxin detrusor and sphincter injection in treatment of overactive bladder syndrome: objective outcome and patient satisfaction. Eur Urol 48 (2005) 984
17. Uebersax J.S., Wyman J.F., Shumaker S.A., McClish D.K., and Fantl J.A. Short forms to assess life quality and symptom distress for urinary incontinence in women: the Incontinence Impact Questionnaire and the Urogenital Distress Inventory. Continence Program for Women Research Group. Neurourol Urodyn 14 (1995) 131
18. Brown J.S., McNaughton K.S., Wyman J.F., Burgio K.L., Harkaway R., Bergner D., et al. Measurement characteristics of a voiding diary for use by men and women with overactive bladder. Urology 61 (2003) 802
19. Sahai A., Khan M.S., and Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 177 (2007) 2231
20. Griffiths D., Kondo A., Bauer S., Diamant N., Liao L., et al. Dynamic testing. In: Abrams P., Cardoza L., Khoury S., and Wein A. (Eds). Incontinence (2005), Health Publications Ltd, Paris 587-675